American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting最新文献_第3页

Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing. 转移性乳腺癌的临床试验解码：最佳治疗序列的实用见解。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-14 DOI: 10.1200/EDBK-25-100053

Chiara Corti, Hope S Rugo, Sara M Tolaney

{"title":"Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing.","authors":"Chiara Corti, Hope S Rugo, Sara M Tolaney","doi":"10.1200/EDBK-25-100053","DOIUrl":"https://doi.org/10.1200/EDBK-25-100053","url":null,"abstract":"The art of sequencing therapy in the management of breast cancer is a multifaceted challenge that demands the careful integration of clinical trial data, real-world evidence, and individualized patient factors to guide treatment decisions. As the therapeutic landscape evolves rapidly with new agents and combinations, clinicians are confronted with critical decisions on how best to order treatments to maximize benefit, minimize toxicity, and preserve future options. For patients with estrogen receptor-positive (ER+) disease, this review discusses how emerging resistance patterns after cyclin-dependent kinase 4 and 6 inhibitors require careful re-evaluation of subsequent endocrine and targeted therapies, as well as chemotherapy, emphasizing the need for evidence-based strategies and ethical crossover designs in clinical trials. In addition, for both ER+ and ER- metastatic breast cancer (MBC) with nonoverexpressed human epidermal growth factor receptor 2 (HER2), this review highlights pivotal trials investigating antibody-drug conjugates (ADCs)-including trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan-and the challenges related to control arm selection and crossover that may affect outcome interpretation. Finally, for patients with HER2-positive disease, the review explores first-line and maintenance strategies-including insights from landmark trials like CLEOPATRA and PATINA-and addresses the impact of brain metastases on sequencing decisions. By critically appraising current data and identifying gaps in biomarker-guided and sequencing-specific strategies, this review provides practical insights to inform clinical practice and optimize personalized treatment plans for patients with MBC.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e100053"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship. 免疫肿瘤学中的肠道微生物群：医学肿瘤学家的实用指南，重点是抗生素管理。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-04-22 DOI: 10.1200/EDBK-25-472902

Arielle Elkrief, Bertrand Routy, Lisa Derosa, Laura Bolte, Jennifer A Wargo, Jennifer L McQuade, Laurence Zitvogel

{"title":"Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship.","authors":"Arielle Elkrief, Bertrand Routy, Lisa Derosa, Laura Bolte, Jennifer A Wargo, Jennifer L McQuade, Laurence Zitvogel","doi":"10.1200/EDBK-25-472902","DOIUrl":"https://doi.org/10.1200/EDBK-25-472902","url":null,"abstract":"The gut microbiota has emerged as a critical determinant of immune checkpoint inhibitor (ICI) efficacy, resistance, and toxicity. Retrospective and prospective studies profiling the taxonomic composition of intestinal microbes of patients treated with ICI have revealed specific gut microbial signatures associated with response. By contrast, dysbiosis, which can be caused by chronic inflammatory processes (such as cancer) or comedications, is a risk factor of resistance to ICI. Recent large-scale meta-analyses have confirmed that antibiotic (ATB) use before or during ICI therapy alters the microbiota repertoire and significantly shortens overall survival, even after adjusting for prognostic factors. These results underscore the importance of implementing ATB stewardship recommendations in routine oncology practice. Microbiota-centered interventions are now being explored to treat gut dysbiosis and optimize ICI responses. Early-phase clinical trials evaluating fecal microbiota transplantation (FMT) from ICI responders or healthy donors have shown that this approach is safe and provided preliminary data on potential efficacy to overcome both primary and secondary resistance to ICI in melanoma, non-small cell lung cancer, and renal cell carcinoma. More targeted interventions including live bacterial products including Clostridium butyricum and Akkermansia massiliensis represent novel microbiome-based adjunct therapies. Likewise, dietary interventions, such as high-fiber diets, have shown promise in enhancing ICI activity. In this ASCO Educational Book, we summarize the current state-of-the-evidence of the clinical relevance of the intestinal microbiota in cancer immunotherapy and provide a practical guide for ATB stewardship.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472902"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

One Step Ahead: Preventing Tumor Adaptation to Immune Therapy. 向前迈进一步：预防肿瘤对免疫治疗的适应。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-07 DOI: 10.1200/EDBK-25-481556

Erica L Braverman, Giuliana P Mognol, Andy J Minn, Dario A A Vignali, Judith A Varner

{"title":"One Step Ahead: Preventing Tumor Adaptation to Immune Therapy.","authors":"Erica L Braverman, Giuliana P Mognol, Andy J Minn, Dario A A Vignali, Judith A Varner","doi":"10.1200/EDBK-25-481556","DOIUrl":"https://doi.org/10.1200/EDBK-25-481556","url":null,"abstract":"Immune checkpoint inhibitors are cancer therapeutics that have shown remarkable success in extending lives in many cancers, including melanoma, MSI-high cancers, and other cancers. However, these therapeutics have not shown benefit for many patients with cancer, especially those with advanced cancer diagnoses. In addition, many patients develop resistance to these therapeutics and/or life-altering adverse events that can include cardiotoxicity, pneumonitis, thyroiditis, pancreatitis, and hepatitis. Extensive efforts to improve cancer care by uncovering mechanisms of resistance to immune therapy in solid tumors have led to identification of new sources of resistance and to the development of new approaches to activate or sustain antitumor immunity. Chronic stimulation of T cells by tumors and by checkpoint inhibitors can lead to a progressive state of T-cell exhaustion. Chronic T-cell activation by the tumor microenvironment (TME) or immune therapeutics can upregulate the expression and function of alternate checkpoints, including the T-cell protein LAG-3. Persistent interferon signaling in the TME can drive epigenetic changes in cancer cells that enable tumors to counter immune activation and disrupt tumor cell elimination. In addition, immune-suppressive macrophages can flood tumors in response to signals from dying tumor cells, further preventing effective immune responses. New clinical developments and/or approvals for therapies that target alternate immune checkpoints, such as the T-cell checkpoint LAG-3; myeloid cell proteins, such as the kinase phosphoinositide 3-kinase gamma isoform; and chronic interferon signaling, such as Jak 1 inhibitors, have been approved for cancer care or shown promise in recent clinical trials.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e481556"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates on Treatments and Management of Nasopharyngeal Carcinoma. 鼻咽癌的治疗和管理进展。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-04-10 DOI: 10.1200/EDBK-25-472460

Melvin L K Chua, Xin Zhang, Kenneth C W Wong, Marret Grégoire, Anna Spreafico, Brigette Ma

{"title":"Updates on Treatments and Management of Nasopharyngeal Carcinoma.","authors":"Melvin L K Chua, Xin Zhang, Kenneth C W Wong, Marret Grégoire, Anna Spreafico, Brigette Ma","doi":"10.1200/EDBK-25-472460","DOIUrl":"https://doi.org/10.1200/EDBK-25-472460","url":null,"abstract":"Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer, where the endemic subtype is strongly associated with Epstein-Barr virus (EBV) infection, whereas emerging data suggest that a subset of nonendemic NPC may be associated with human papillomavirus (HPV) infection. Nonetheless, treatment advances have been driven by clinical trials conducted in endemic NPC, investigating optimal sequencing of chemotherapy and immune checkpoint inhibitors with radiotherapy for locoregionally advanced disease. The preference for induction chemotherapy (IC) in these patients has also led to evolution in the concept of radiotherapy target delineation. Because of its association with EBV, plasma EBV DNA is an archetypal biomarker for endemic NPC, and it is being explored for precise stratification and treatment individualization in several ongoing trials. In the space of recurrent or metastatic-NPC, with the advent of platinum-doublet chemotherapy and anti-PD-1 antibody as the new standard of care, several trials are investigating new immunotherapeutic combinations, bispecific antibodies, and antibody-drug conjugates that have demonstrated promise in early phase trials. An important advance for NPC in 2025 is the update of the 9th version of the TNM staging system, which has introduced several key changes, including downgrading of the TNM stage groupings for localized disease, and splitting of metastatic NPC into IVA and IVB based on the number of metastatic lesions. These revisions would have implications for the treatment and design of future trials. These advances are also relevant to nonendemic NPC, where evidence is inconclusive whether this disease responds differently to current treatments compared with endemic NPC.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472460"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies. 简单如ABC：管理抗体-药物偶联物，双特异性抗体和CAR - t细胞疗法的毒性。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-04-28 DOI: 10.1200/EDBK-25-473916

Michael D Jain, Jeremy S Abramson, Stephen M Ansell

引用次数: 0

When and How Long to Treat Chronic Lymphocytic Leukemia? 慢性淋巴细胞白血病何时治疗，需要多长时间？

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-04-24 DOI: 10.1200/EDBK-25-473656

Carsten U Niemann, Abraham Varghese, Talha Munir, Ellinor Goergen, Barbara Eichhorst

引用次数: 0

Rare Uterine Tumors: What to Do? 罕见的子宫肿瘤：该怎么办？

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1200/EDBK-25-473106

Erin Crane, Stéphanie Gaillard, Martee Leigh Hensley

引用次数: 0

Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward. 局部肌肉浸润性膀胱癌的围手术期治疗选择：向前迈进了一步。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-20 DOI: 10.1200/EDBK-25-472822

Maria J Ribal, Jonathan Rosenberg, Tarek Ajami, Antoni Vilaseca, Leilei Xia, Michal Sternschuss, Anne K Schuckman

{"title":"Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward.","authors":"Maria J Ribal, Jonathan Rosenberg, Tarek Ajami, Antoni Vilaseca, Leilei Xia, Michal Sternschuss, Anne K Schuckman","doi":"10.1200/EDBK-25-472822","DOIUrl":"10.1200/EDBK-25-472822","url":null,"abstract":"Muscle-invasive bladder cancer (MIBC) is an aggressive disease, with substantial recurrence risk after radical cystectomy and pelvic lymph node dissection alone. In cisplatin-eligible patients, administration of neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy has been shown to improve overall survival (OS) and has become the standard of care. Nevertheless, approximately 40%-50% of patients will still experience disease recurrence after curative-intent treatment. Moreover, a significant proportion of patients with MIBC are ineligible for cisplatin and represent a challenging clinical scenario. In recent years, different strategies aiming to improve patient outcomes by incorporating immune checkpoint inhibitors in the treatment paradigm were explored. Two key management approaches emerged: neoadjuvant chemotherapy with risk-adapted adjuvant immunotherapy and universal perioperative immunotherapy-based treatment. We review the rationale, current evidence, challenges, and future directions for the perioperative management of muscle-invasive urothelial carcinoma.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472822"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration. 非小细胞肺癌的双特异性抗体：从靶向创新到现实世界的整合。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-21 DOI: 10.1200/EDBK-25-472792

Jennifer W Carlisle, Zachary Wolner, Sagal Pannu, Carley Mitchell, Melinda Hsu, Ayesha Aijaz, Melissa Johnson, Abdul Rafeh Naqash

{"title":"Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration.","authors":"Jennifer W Carlisle, Zachary Wolner, Sagal Pannu, Carley Mitchell, Melinda Hsu, Ayesha Aijaz, Melissa Johnson, Abdul Rafeh Naqash","doi":"10.1200/EDBK-25-472792","DOIUrl":"https://doi.org/10.1200/EDBK-25-472792","url":null,"abstract":"Bispecific antibodies have ushered in a transformative era in treating non-small cell lung cancer (NSCLC), enabling dual-pathway targeting with promising clinical outcomes in previously refractory disease subsets. Recent US Food and Drug Administration approvals-including amivantamab, an epidermal growth factor receptor (EGFR)/mesenchymal-epithelial transition factor-targeting monoclonal antibody for EGFR exon 20 insertions and frontline EGFR-mutant (Exon 19 and 21) NSCLC, and zenocutuzumab for tumors harboring neuregulin 1 fusions-highlight their expanding therapeutic footprint. However, a new spectrum of on-target toxicities and implementation challenges are essential considerations as part of this innovation. This review dissects the evolving clinical data for bispecific antibodies in NSCLC, focusing on amivantamab, and provides a practical framework for managing dermatologic, infusion-related, and class-specific adverse events. We explore quality-of-life outcomes, financial toxicity, and the role of subcutaneous formulations in improving patient adherence and treatment experience. Furthermore, we highlight an emerging PD-1/vascular endothelial growth factor-A bispecific antibody (ivonescimab) and its potential to reshape frontline therapy paradigms in NSCLC. By integrating clinical trial evidence with real-world considerations, this review aims to equip oncologists with the tools to optimize the use of bispecific antibodies in NSCLC and guide future therapeutic integration.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472792"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Driving Knowledge to Action: Building a Better Future With Artificial Intelligence-Enabled Multidisciplinary Oncology. 将知识转化为行动：用人工智能支持的多学科肿瘤学建立更美好的未来。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-02 DOI: 10.1200/EDBK-25-100048

Arturo Loaiza-Bonilla, Nikhil Thaker, Caroline Chung, Ravi Bharat Parikh, Shawn Stapleton, Piotr Borkowski

{"title":"Driving Knowledge to Action: Building a Better Future With Artificial Intelligence-Enabled Multidisciplinary Oncology.","authors":"Arturo Loaiza-Bonilla, Nikhil Thaker, Caroline Chung, Ravi Bharat Parikh, Shawn Stapleton, Piotr Borkowski","doi":"10.1200/EDBK-25-100048","DOIUrl":"https://doi.org/10.1200/EDBK-25-100048","url":null,"abstract":"Artificial intelligence (AI) is transforming multidisciplinary oncology at an unprecedented pace, redefining how clinicians detect, classify, and treat cancer. From earlier and more accurate diagnoses to personalized treatment planning, AI's impact is evident across radiology, pathology, radiation oncology, and medical oncology. By leveraging vast and diverse data-including imaging, genomic, clinical, and real-world evidence-AI algorithms can uncover complex patterns, accelerate drug discovery, and help identify optimal treatment regimens for each patient. However, realizing the full potential of AI also necessitates addressing concerns regarding data quality, algorithmic bias, explainability, privacy, and regulatory oversight-especially in low- and middle-income countries (LMICs), where disparities in cancer care are particularly pronounced. This study provides a comprehensive overview of how AI is reshaping cancer care, reviews its benefits and challenges, and outlines ethical and policy implications in line with ASCO's 2025 theme, Driving Knowledge to Action. We offer concrete calls to action for clinicians, researchers, industry stakeholders, and policymakers to ensure that AI-driven, patient-centric oncology is accessible, equitable, and sustainable worldwide.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e100048"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0